Verbruggen LC, Wang Y, Armenian SH, Ehrhardt MJ, van der Pal HJH, van Dalen EC, van As JW, Bardi E, Baust K, Berger C, Castagnola E, Devine KA, Gebauer J, Marchak JG, Glaser AW, Groll AH, Haeusler GM, den Hartogh J, Haupt R, Hjorth L, Kato M, Kepák T, Koopman MMWR, Langer T, Maeda M, Michel G, Muraca M, Nathan PC, van den Oever SR, Pavasovic V, Sato S, Schulte F, Sung L, Tissing W, Uyttebroeck A, Mulder RL, Kuehni C, Skinner R, Hudson MM, Kremer LCM
Pediatr Blood Cancer 67 (12) e28702 [2020-12-00; online 2020-09-23]
Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19.